Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RTX-GRT7039 in Osteoarthritis of the Knee
NCT05248386Phase 3
Key facts
- Status
- Completed
- Start
- Aug 2022
- Primary completion
- Nov 2024
- Countries
- 9
- Sponsor
- Grünenthal GmbH
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Drugs
- RTX-GRT7039
- Conditions
- osteoarthritis (OA)
01
Overview
Phase 3, randomised, double-blind trial in osteoarthritis (OA) comparing RTX-GRT7039 with Placebo (2 arms). Primary endpoint: WOMAC Pain Subscale Score at 12 weeks. Started Aug 2022; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
RTX-GRT7039
Intra-articular injections of RTX-GRT7039
Placebo
Intra-articular injections of placebo
03
Who it enrols
Adults with osteoarthritis of the knee and insufficient pain relief with previous standard of care, excluding those with past joint replacement surgery, significant trauma, or other specific knee conditions.
04
Endpoints
Primary
WOMAC Pain Subscale Score
Secondary
WOMAC Pain Subscale Score
WOMAC Physical Function Subscale Score
Beyond the preview
Go deeper on NCT05248386.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05248386.